EA201991818A1 - CANCER TREATMENT - Google Patents

CANCER TREATMENT

Info

Publication number
EA201991818A1
EA201991818A1 EA201991818A EA201991818A EA201991818A1 EA 201991818 A1 EA201991818 A1 EA 201991818A1 EA 201991818 A EA201991818 A EA 201991818A EA 201991818 A EA201991818 A EA 201991818A EA 201991818 A1 EA201991818 A1 EA 201991818A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
erdafitinib
provides
present
treating cancer
Prior art date
Application number
EA201991818A
Other languages
Russian (ru)
Inventor
Ким Стейкенс
Хуан Хосе Перес Руиксо
Питер Мари З. Де Порре
Энджели Нарайан Эведхэни
Иоанн Лорьо
Арлен О. Сифкер-Радтке
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201991818A1 publication Critical patent/EA201991818A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

В настоящем изобретении предусмотрен способ лечения рака с помощью эрдафитиниба.The present invention provides a method for treating cancer with erdafitinib.

EA201991818A 2017-12-20 2018-02-02 CANCER TREATMENT EA201991818A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
EA201991818A1 true EA201991818A1 (en) 2020-02-05

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991818A EA201991818A1 (en) 2017-12-20 2018-02-02 CANCER TREATMENT

Country Status (5)

Country Link
EA (1) EA201991818A1 (en)
MA (1) MA47408B1 (en)
PT (1) PT3576740T (en)
TW (1) TWI798199B (en)
WO (1) WO2018141921A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190826A1 (en) * 2018-09-21 2021-06-16 Янссен Фармацевтика Нв CHOLANGIOCARCINOMA TREATMENT
JP2022515197A (en) * 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド 7-((3,5-dimethoxyphenyl) amino) quinoxaline derivative as an FGFR inhibitor for treating cancer
SG11202107850VA (en) * 2019-02-12 2021-08-30 Janssen Pharmaceutica Nv Cancer treatment
WO2020190606A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
MX2021011943A (en) * 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma.
EP3976833A4 (en) * 2019-05-31 2023-07-05 QED Therapeutics, Inc. Methods of treating urinary system cancers
WO2021119108A1 (en) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
WO2021160764A1 (en) * 2020-02-12 2021-08-19 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (en) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Also Published As

Publication number Publication date
TWI798199B (en) 2023-04-11
PT3576740T (en) 2023-08-18
WO2018141921A1 (en) 2018-08-09
TW201839399A (en) 2018-11-01
MA47408B1 (en) 2023-08-31
MA47408A (en) 2019-12-11

Similar Documents

Publication Publication Date Title
MX2019007030A (en) Compositions and methods for treating cancer.
EA201991818A1 (en) CANCER TREATMENT
EA201992497A1 (en) K-Ras MODULATORS
PH12017501999A1 (en) K-ras modulators
MD3209310T2 (en) Compositions comprising bacterial strains
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MD3209381T2 (en) Compositions comprising bacterial strains
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
EA201990296A1 (en) ANTIBODIES AGAINST SIGLEC-7 FOR CANCER TREATMENT
BR112017000130A2 (en) method for mitigating toxicity associated with notch pathway inhibition and cancer treatment method
BR112018000776A2 (en) Methods for cancer treatment using apilimod
MX2017016114A (en) Methods of treating or preventing a proteopathy.
MA40457A (en) Drug combinations to treat multiple myeloma
EA202091881A1 (en) COMPOUNDS FOR PAIN TREATMENT
MX2020006297A (en) Cd19 variants.
KR102377742B1 (en) cancer treatment
EA202191086A1 (en) COMBINED MELANOMA THERAPY
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
JO3541B1 (en) Medical treatments based on anamorelin
MX2022007955A (en) Cancer treatment.
BR112019004276A2 (en) Methods For Treating Ovarian Cancer
EP3674398A4 (en) Echovirus for treating tumor
EA202192163A1 (en) CANCER TREATMENT
EA202190833A1 (en) BT1718 FOR CANCER APPLICATION
CL2019000697S1 (en) Induction heater